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The aim of this paper was to propose key steps for community pharmacist integration into a patient care pathway for chronic
obstructive pulmonary disease (COPD) management. A literature search was conducted to identify publications focusing on the role
of the community pharmacist in identiﬁcation and management of COPD. The literature search highlighted evidence supporting an
important role for pharmacists at each of the four key steps in the patient care pathway for COPD management. Step 1 (primary
prevention): pharmacists are ideally placed to provide information on disease awareness and risk prevention campaigns, and to
encourage lifestyle interventions, including smoking cessation. Step 2 (early detection/case ﬁnding): pharmacists are often the
ﬁrst point of contact between the patient and the healthcare system and can therefore play an important role in the early
identiﬁcation of patients with COPD. Step 3 (management and ongoing support): pharmacists can assist patients by providing
advice and education on dosage, inhaler technique, treatment expectations and the importance of adherence, and by supporting
self-management, including recognition and treatment of COPD exacerbations. Step 4 (review and follow-up): pharmacists can
play an important role in monitoring adherence and ongoing inhaler technique in patients with COPD. In summary, pharmacists are
ideally positioned to play a vital role in all key stages of an integrated COPD patient care pathway from early disease detection to the
support ofmanagement plans, including advice and counselling regardingmedications, inhaler technique and treatment adherence.
Areas requiring additional consideration include pharmacist training, increasing awareness of the pharmacist role, administration and
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Introduction
As the fourth leading cause of mortality worldwide, chronic
obstructive pulmonary disease (COPD) represents a major
public health challenge [2]. Indeed, in 2012, more than
3 million people worldwide died of COPD, equating to 6% of
all deaths globally in that year [3]. Although preventable and
treatable [2], the burden of COPD is set to continue or worsen,
with estimates from the World Health Organization (WHO)
predicting that it will be the third leading cause of mortality
worldwide by 2030 [4, 5]. In addition to its impact on
patients' lives, COPD is associated with spiralling healthcare
resource use and costs [2]. For example, in the EU total
COPD-related expenses for outpatient and inpatient care are
approximately €4.7 and €2.9 billion/year, respectively [5].
In the UK, the costs associated with COPD are estimated to
exceed £800 million [6]. In the USA, more than 26 million
people are estimated to have COPD but almost half of these
are undiagnosed [7]. Therefore, there remains much to do in
terms of early detection and treatment of COPD, before
patients reach symptomatic and costly disease stages [8].
The treatment of patients with COPD is complex and
encompasses many different issues, such as early and correct
diagnosis, primary and secondary prevention, and multiple
pharmaceutical and nonpharmaceutical interventions. One
of the most important issues, however, is motivating patients
fully to participate in and adhere to their individualized man-
agement plan, including maintenance and self-management
aspects, such as lifestyle adaptation.
Most patients with COPD are seen in primary care but
resource pressures within the healthcare service may limit
physician–patient contact time [9]. An integrated approach
which utilizes contact time with other healthcare services, in-
cluding community pharmacists, may therefore be beneﬁcial
for the efﬁcient delivery of COPD management plans. Given
their skill set, frequent contact with patients and expertise re-
garding available treatments, pharmacists may be well placed
to have an input into the management and motivation of pa-
tients with COPD. Added to this is the convenience of the
community pharmacy to patients, in terms of location, open-
ing times and ‘open door’ consultation opportunities [10].
The present review proposes key steps of an integrated
patient care pathway in which community pharmacists are
best placed to help to optimize the diagnosis and manage-
ment of COPD (Figure 1). In doing so, the evidence for the
role of the pharmacist in primary prevention, screening and
early diagnosis, management and follow-up/review stages of
the pathway is summarized.
Methods
A literature review was conducted to ﬁnd publications focus-
ing on the role of the community pharmacist in identifying,
managing and following up patients with COPD, as well as
on the pharmacological treatments used in COPD and poten-
tial challenges associated with community pharmacist care.
PubMed searches were used to identify relevant English-
language papers over the past 10 years. Key search terms
included, but were not limited to, chronic obstructive
pulmonary disease, COPD, management, role of pharmacist,
community pharmacist, spirometry, and inhaler techniques.
Further articles were identiﬁed by cross-referencing; key
guidelines/health reports were also consulted. Appropriate
information and data are included here, and the majority of
the references cited were published within the last 5 years.
Results
Background: what do we mean by an integrated
patient care pathway?
Integrated patient care pathways, also referred to as coordinated
care pathways or care maps, may be deﬁned as ‘structured
multidisciplinary care plans’, detailing key steps in the care of
a patient with a speciﬁc illness [11]. Integrated patient care
pathways were introduced to aid the translation of national
guidelines into local management protocols and subsequent
implementation into daily clinical practice. As well as
promotingmore focused patient care, this approach encourages
multidisciplinary communication and care planning, which
might ultimately translate into improved patient outcomes,
e.g. quality of life, reduced complications or hospital
admissions, better patient satisfaction and improved treatment
adherence [11–13]. In general, the steps constituting a patient
care pathway include, but are not limited to: (i) primary
prevention; (ii) screening and diagnosis; (iii) management of
disease; and (iv) follow-up and review of care. The following
discusses the potential role that canbe played by the community
pharmacist for each of these four steps in a patient care pathway
for COPD.
Step 1: primary prevention
Cigarette smoking is the leading cause of COPD in the
Western world (85% of all COPD cases are attributed to
smoking) [2, 14, 15]. Compared with nonsmokers, cigarette
smokers have a higher prevalence of respiratory
symptoms/lung function abnormalities, a greater annual
decline in their forced expiratory volume in 1 s (FEV1) proﬁle,
and are at greater risk of death from COPD [2, 16]. Commu-
nity pharmacists play a vital role in providing information
on available smoking cessation programmes.
Local pharmacies are ideal venues for disease awareness
and risk prevention campaigns [10, 14]. In general, the level
of awareness of COPD, its symptoms and its association with
cigarette smoking is inadequate, with many believing that
dyspnoea and limitations in performing daily activities or
exercise are a simple part of the ageing process [14]. As such,
an important aspect of disease education is communicating
the association between cigarette smoking and COPD, and
the impact of COPD symptoms on daily activities and overall
quality of life. Community pharmacists can assist by
providing behavioural support to help with smoking
cessation and by advising individuals on the correct use of
nicotine replacement therapies [2, 17]. Both pharmacological
treatment and counselling have been shown to be effective
strategies in smoking cessation [2, 17, 18]. In a recent
meta-analysis of ﬁve studies involving 1426 smokers,
pharmacist-based interventions were associated with
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improved abstinence rates compared with a control group
(relative risk 2.21, 95% conﬁdence interval [CI] 1.49, 3.29)
[19].
While smoking cessation is one of the key elements in
COPD risk prevention, pharmacist-directed disease
education (in the form of awareness and risk prevention
campaigns or motivating self-management/medication
adherence) may serve as an ideal portal to emphasize
simultaneously the beneﬁts of general lifestyle interven-
tions. Healthy lifestyle options, including diet/nutrition,
weight management and physical activity [20–22], can
help to prevent additional complications arising from any
chronic disease and reduce the risk of mortality [23]. There
are few data reporting lifestyle outcomes in patients with
COPD as a result of pharmacist counselling. One study
showed that patients with COPD who received structured
intervention (including disease and medication education,
inhaler technique, exercise and relaxation techniques) by
a clinical pharmacist had no signiﬁcant difference in
their body mass index compared with patients who
received usual outpatient care [20]. A more recent study
in India, however, demonstrated an improvement in all
subscales of a questionnaire (St George's Respiratory
Questionnaire [SGRQ]) that assessed quality of life (i.e.
symptoms, activity and impact) in patients receiving phar-
macist intervention, which included an emphasis on med-
ication compliance, smoking cessation, simple exercise and
the correct use of inhaler devices, compared with control
patients who received standard hospital care [24]. Further
research focusing speciﬁcally on pharmacist-led lifestyle
counselling in COPD and associated outcomes is therefore
of interest.
Step 2: early detection/case finding
Timely COPD diagnosis is important because it can
result in earlier intervention (pharmacological or
nonpharmacological) that may lead to improved quality
of life and reduced healthcare burden [8, 14]. Community
pharmacists can play an important role in the early
diagnosis of COPD, as pharmacists are often the ﬁrst point
of contact between the patient and the healthcare system.
Based on a patient's needs when presenting to a pharmacist
(e.g. advice for breathlessness) or medication needs (e.g. a
cough remedy or nicotine replacement therapy), the
community pharmacist can screen for COPD via comple-
tion of a validated disease risk assessment questionnaire
(e.g. COPD Population Screener) [25] and spirometry
testing; if appropriate, the pharmacist may offer lifestyle
advice and refer that patient to their physician for conﬁr-
matory diagnosis and treatment [10, 26, 27]. Studies show-
ing that trained community pharmacists are able to
perform accurate and reproducible spirometry screenings
[28] are supported by a recent evidence-based review
demonstrating acceptable repeatability of spirometry test-
ing (based on the American Thoracic Society/European
Respiratory Society guideline standards) by pharmacists in all
eight studies included in the analysis [29]. Moreover, two recent
Figure 1
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publications showed that trained community pharmacists are
able to detect individuals at high risk of COPD effectively via
COPD case-ﬁnding services [26, 27]. Indeed, UK ﬁndings
revealed that targeted screening could identify one patient with
moderate COPD for every two individuals screened, and that
early identiﬁcation led to cost savings [26]. In the Spanish
case-ﬁnding study, whereby community pharmacists received
16 h of COPD and spirometry training, 63.4% (N = 1456) of
programme participantswere found to be at a high risk of COPD
[high risk was deﬁned as a ‘yes’ answer to ≥3 questions relating
to age, smoking exposure and symptoms on a ﬁve-item Global
Initiative for Chronic Obstructive Lung Disease (GOLD) screen-
ing questionnaire]; of these, 282 (19.8%) participants had
prebronchodilator airﬂow limitation (FEV1/forced vital capacity
<0.70), as conﬁrmed by spirometry, and were requested to
contact their primary care physician [27]. In this particular
study, the need for improvement in collaboration between
primary care physicians and the community pharmacies was
emphasized.
Step 3: management and ongoing support
Once a conﬁrmatory diagnosis of COPD has been obtained
and the patient has been prescribed appropriate treatment
by their physician, the pharmacist can assist patients with
disease management, not only by dispensing medications,
but also by providing advice and education on dosage,
inhaler technique, treatment expectations and the impor-
tance of adherence, and by supporting self-management
[10, 14, 15]. Patients with long-term conditions such as
COPD are also encouraged to receive a yearly ﬂu vaccina-
tion [30]. Pharmacists can be key drivers in achieving ﬂu
vaccination targets, especially in these patient groups who
tend to visit pharmacies more frequently. However, a recent
report of a UK (London)-based pharmacy initiative that
compared annual inﬂuenza vaccine uptake from before
pharmacy vaccination was introduced (from 2011) to after
its introduction (2013–2015) showed no signiﬁcant change
in uptake for any of the risk groups studied, including
chronic respiratory disease; nevertheless, economic beneﬁts
were incurred compared with general practitioner (GP)
vaccine delivery [31].
Important elements of an optimal pharmacotherapeutic
regimen. What constitutes an effective treatment? Simply,
this is a therapy that a patient takes as prescribed over the
long term because it is easy to administer and effectively
reduces day-to-day symptoms, and because patients are
aware of the potential long-term beneﬁts in terms of
reductions in exacerbation risk (with exacerbation deﬁned
as an acute event characterized by worsening respiratory
symptoms beyond normal day-to-day variations, leading to
a change in medication) and lung function decline. Of
course, this simple answer constitutes a realm of complex
and interweaving components.
Overview of pharmacotherapy. Over recent years, signiﬁcant
advances have been made in COPD treatment, with
numerous pharmacological options available that serve to
provide individualized treatment plans. The GOLD Strategy
for the Diagnosis, Management, and Prevention of Chronic
Obstructive Pulmonary Disease document provides
pharmacological treatment recommendations for patients
based on a combination of symptomatic assessment,
spirometric classiﬁcation and/or risk of exacerbations [2].
Based on this combined assessment, patient groups are
categorized as ‘low risk, fewer symptoms’ (Group A), ‘low
risk, more symptoms’ (Group B), ‘high risk, fewer
symptoms’ (Group C) and ‘high risk, more symptoms’
(Group D). Typically, low-risk patients are those with mild
or moderate airﬂow limitation and/or 0–1 exacerbation/year
and no hospitalization for exacerbations, whereas high-risk
patients are those with severe or very severe airﬂow
limitation and/or ≥2 exacerbations/year or ≥1 exacerbation
necessitating hospitalization.
Most low-risk COPD patient groups (i.e. GOLD Groups
A and B) can be managed with long-acting, inhaled
bronchodilators as a ﬁrst-choice or alternative-choice main-
tenance treatment, i.e. long-acting β2-agonists (LABAs; e.g.
salmeterol, formoterol and indacaterol) or long-acting mus-
carinic antagonists (LAMAs; e.g. tiotropium, glycopyrronium
and umeclidinium) [2]. Owing to their reported effects in
terms of improvement in lung function, patient-reported
outcomes and exacerbation rates, LABAs and LAMAs are
central to the management of COPD [2]. While there is
evidence suggesting that some of the newer LABAs (e.g.
indacaterol) may provide greater improvements over LAMAs
(e.g. tiotropium) in terms of symptoms [32], and that LAMAs
(e.g. tiotropium) may provide greater improvements over
LABAs (e.g. salmeterol or indacaterol) in terms of exacerba-
tion rates [33, 34], the choice of treatment will depend on
availability and individual patient response [2].
Treatment can then be intensiﬁed according to GOLD
patient group by adding a second bronchodilator agent of a
different class (e.g. LABA/LAMA ﬁxed-dose combinations),
the addition of an inhaled corticosteroid (ICS) and by the
use of rescue medication (as required) to allow patients to
manage occurrences of worsening symptoms. For example,
in patients categorized as high risk (GOLD Groups C and D),
ICS/LABA and/or a LAMA are recommended as ﬁrst-choice
therapies [2]. LABA/LAMA combinations are associated
with potent bronchodilation, irrespective of whether the
patient is considered to be low- or high risk [35–37].
Individual LABA/LAMAs have also been shown signiﬁcantly
to improve symptoms (indacaterol/glycopyrronium [35]
and tiotropium/olodaterol [38]), health status (indacaterol/
glycopyrronium [35], tiotropium/olodaterol [38], and
umeclidinium/vilanterol [39]) and exacerbation rates
(indacaterol glycopyrronium [40]), compared with single
agents. Further, indacaterol/glycopyrronium has been shown
to be superior to ICS/LABA in terms of lung function and
symptoms [41, 42], and in higher-risk patients in terms of
exacerbations and health status [2, 43].
In spite of GOLD recommendations concerning ICS use in
high-risk populations only [2], and their association with a
heightened risk of pneumonia in COPD patients [44], ICSs
are prescribed across all severities of COPD, independent of
exacerbation risk [45]. Nevertheless, data are emerging that
show that it is possible to withdraw ICSs from treatment
regimens in low-risk patients in whom they are not indicated
[46] and in high-risk patients in whom theremay be concerns
about the risk of pneumonia [47], without having a negative
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impact on exacerbation risk, provided that adequate
bronchodilation is in place.
Additional maintenance treatment options in COPD
include the phosphodiesterase-4 inhibitors (e.g. roﬂumilast)
and the mucolytics (e.g. carbocysteine or N-acetylcysteine),
both recommended by GOLD for patients with severe-to-
very-severe airﬂow limitation and frequent exacerbations
not adequately controlled by long-acting bronchodilators
[2]. Management options for people suffering an exacerba-
tion are short-acting bronchodilators, oral or intravenous
corticosteroids, and/or antibiotics when there are signs of
bacterial infection during such episodes [2].
Inhaler characteristics. Another important factor to
consider when discussing optimal drug therapy is the
inhaler used to administer the medication, as incorrect use
of an inhaler can lead to suboptimal drug delivery to the
lungs and reduced disease control [48, 49]. Different inhaler
types have their own advantages and disadvantages. For
example, one of the key beneﬁts of dry-powder inhalers
(DPIs) compared with pressurized metered-dose inhalers is
that they are breath actuated and therefore overcome the
potential problems of coordination of actuation and
inhalation; however, breath-actuated inhalers require
patients to generate sufﬁcient inspiratory effort to overcome
the internal resistance of the inhaler [48]. Key features
affecting patients' preference for a speciﬁc inhaler device
include perceived device efﬁcacy, ease of use and its
convenience [50]. Various studies have assessed the relative
patient preference for different DPIs, with variable results
[48, 51, 52]. Irrespective of how well designed an inhalation
device might be, it is important to recognize that initial
appropriate inhaler technique may be lost over time [53].
This reinforces the need for continued education/
monitoring of inhaler use and represents an important area
in which community pharmacists can assist in COPD
management.
Pharmacist role in supporting a management plan.
Inhaler technique. Pharmacists can play a vital role in
supporting patients with their COPD management plan,
including monitoring to ensure the appropriate and
effective use of medications to minimize exacerbation/
hospitalization risk [54]. For many patients with COPD,
mastering inhaler technique is a major challenge, which
can impede effective treatment [14]. Some patients require
multiple inhalers, each with a different method of use, as
well as other medications for comorbid diseases.
Pharmacists can help by instructing patients on how to
use their inhaler(s) properly, regularly checking technique
and intervening where necessary [55]. Moreover, by
reviewing the number of daily doses and monitoring
unnecessary device changes, a pharmacist can potentially
make recommendations for medication changes, e.g. to a
ﬁxed-dose combination product (several such products are
now approved) [14].
In the Pharmaceutical care for patients with COPD
(PHARMACOP) 3-month study, conducted in 170 commu-
nity pharmacies in Belgium, patients with COPD were
randomized to a protocol-based pharmacist intervention
(n = 371), which focused on inhalation technique and
adherence to maintenance therapy, or a control (usual phar-
macist care) group (n = 363) [54]. A protocol-based pharma-
cist intervention was associated with signiﬁcant
improvements in inhaler technique (a 13.5% increase in the
percentage of correct steps performed compared with the
control group, P < 0.0001), adherence to maintenance medi-
cation, as assessed by the Medication Reﬁll Adherence score
(treatment difference of 8.51, P< 0.0001) and hospitalization
rate (nine events with the pharmacist intervention vs. 35
events in the control group; estimated rate ratio 0.28, P =
0.003). In a separate cost-effectiveness analysis, the
PHARMACOP intervention resulted in overall costs per pa-
tient of €2221 within a 1-year timeframe, compared with
€2448 for usual care, leading to a cost saving per patient of
€227 [56].
Self-management/action plans. Community pharmacists
also support patients in the context of ‘self-management’
plans, helping to empower those with COPD to take control
of their condition [57]. One deﬁnition of self-management
is ‘… manage the symptoms, treatment, physical and
psychosocial consequences and life style changes inherent
in living with a chronic condition ... [the] ability to monitor
one's condition and to effect the cognitive, behavioural and
emotional responses necessary to maintain a satisfactory
quality of life’ [58].
In COPD, self-care usually refers to the management of
acute exacerbations but also includes lifestyle interventions
(e.g. smoking cessation, exercise, nutrition and stress man-
agement) [57]. COPD exacerbations have a negative impact
on patient quality of life and are associated with increased
hospital admission rates, accelerated lung function decline
and signiﬁcant mortality in cases requiring hospital admis-
sion [2, 56, 59–61]. As such, action plans that assist patients
with recognizing exacerbation onset and encourage prompt
management can be of considerable beneﬁt to the patient
and the healthcare system (Figure 2 shows an example from
the UK) [57]. In this regard, pharmacists in the UK can refer
patients to their GP to obtain a COPD rescue pack that
contains home supplies of antibiotics and corticosteroids
to be taken in the event of an exacerbation [62, 63]. Pharma-
cists are also well placed to assist patients in agreeing an
action plan, advising on how to recognize an acute exacer-
bation and when/how to use the rescue pack, as well as
monitoring use of both maintenance and rescue medication
[54, 57].
The impact of pharmacy-based intervention and self-
management has been investigated in patients with COPD.
Studies have demonstrated beneﬁts with regard to improved
quality of life, increased medication adherence, and reduc-
tions in doctor visits and hospitalization rates [15, 20, 63].
Furthermore, an update of the Cochrane systematic review
of self-management for patients with COPD (comprising 23
studies and 3189 participants) demonstrated, that compared
with usual care, self-management interventions were associ-
ated with improvements in health-related quality of life
(HRQoL), as assessed by SGRQ total score (mean treatment
difference  3.51; 95% CI 5.37, 1.65), and breathlessness,
as measured by the modiﬁed Medical Research Council scale
(mean treatment difference  0.83; 95% CI 1.36, 0.30),
and a lower probability of respiratory hospitalizations (odds
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ratio 0.57; 95% CI 0.43, 0.75) [57]. In this review, no signiﬁ-
cant effect of self-management vs. usual care was reported
for all-cause hospitalizations or mortality [64].
Step 4: review and follow-up
Challenge of treatment adherence. Central to a community
pharmacist's role in the framework of an integrated COPD
care service is monitoring follow-up, which may coincide
with the collection of prescriptions [63]. In the UK, annual
systematic reviews of both inhaler technique (discussed
above) and medications is recommended [63, 65]. One
aspect of the medication review relates to treatment
adherence, which is a key area for community pharmacist
involvement [14, 21].
For many chronic illnesses, including COPD, non-
adherence is a major challenge (adherence to treatment
averages 50%) [14, 21]. Non-adherence is associated with
adverse clinical/economic outcomes [66] and may arise for
many reasons, including: complex treatment/dosing regi-
mens, difﬁculties with using devices (e.g. inhalers), adverse
treatment effects, concerns about drug dependency, and
denial of illness severity [14, 67]. The fact that community
pharmacists are in a position to monitor long-term
dispensing data provides them with the necessary tools to
identify patients who show signs of non-adherence and inter-
vene as necessary [21].
Optimizing management. The Medication Monitoring and
Optimization (MeMO) programme in the Netherlands is a
targeted pharmacist programme for improving adherence to
long-term therapy for the management of osteoporosis,
cardiovascular disease and asthma/COPD [21]. The initial
phase of the programme encompasses structured
counselling sessions with patients and is followed by
monthly monitoring of treatment adherence via the
pharmacy dispensing database. Results from the MeMO
asthma/COPD programme showed a signiﬁcant decrease in
the frequency of exacerbations (0.82 exacerbations/
patient/year) as well as a decrease in total healthcare costs of
€333 per patient, but minimal or no changes in terms of
adherence or quality of life [68]. The latter ﬁndings were
similar to those of a US study in patients with COPD or
asthma that compared pharmacist care, usual care and a
peak expiratory ﬂow rate monitoring control group [69]. In
this particular study, which assessed patients at 6 months
and 12 months, there were no between-group differences in
treatment compliance or HRQoL, although a signiﬁcant
difference in treatment satisfaction was recorded in the
pharmacist care group. Notably, for patients with
osteoporosis, the MeMO programme resulted in a
signiﬁcant reduction in treatment discontinuation (from
31.7% to 16.1%, P < 0.001) [21]. Furthermore, in a recent
study of 154 respiratory patients (aged 18–65 years) that
examined the effects on treatment satisfaction and
Figure 2
Example of a typical UK-based chronic obstructive pulmonary disease (COPD) action plan (example action plan reproduced with the permission of
Dr Rupert Jones [57])
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adherence of patient counselling at discharge and follow-up
by a pharmacist, signiﬁcant differences were reported in
favour of pharmacist counselling [70]. The results showed a
42.9% increase in medication adherence in the study group
compared with the control group, as well as a 33.5%
increase in treatment satisfaction. As discussed above, the
PHARMACOP study also demonstrated a signiﬁcant
improvement in medication adherence following a
protocol-based pharmacist intervention [54].
In the UK, pharmacy services, including the Medicines
Use Review (MUR) [71] and Prescription Intervention Service
and the New Medicine Service (NMS) [72], aim to improve
safety and treatment adherence, and reduce medicine
wastage by supporting patients with long-term conditions.
The MUR service consists of pharmacists who conduct
structured adherence-focused reviews with patients on
multiple medications for long-term conditions [71]. The
NMS, which has been shown signiﬁcantly to improve
adherence, supports patients who have been prescribed a
medicine for the ﬁrst time for certain conditions, including
COPD, and comprises three patient–pharmacist appointments,
conducted fortnightly [72, 73].
Given that even a brief counselling session with
patients on the importance of taking medications can result
in signiﬁcant improvements in adherence, more intensive,
individually tailored, pharmacist-delivered interventions,
such as those described above, should result in beneﬁcial
outcomes. Indeed, one study reported positive results with
individualized, pharmacist–patient educational sessions on
COPD, medications and inhaler techniques, and the
construction of customized action plans [20].
Are there any limitations associated with
community pharmacist intervention?
Ensuring the continuity of healthcare quality. While
pharmacist care/intervention helps to provide beneﬁts in
terms of medication adherence, patient satisfaction with
treatment and various clinical advantages, such as a reduced
number of hospitalizations or improvements in aspects of
HRQoL among patients with COPD [22], there may be a
number of areas in the context of expanding community
pharmacy services that require further focus and planning.
For example, in the aforementioned UK pilot ﬂu vaccination
programme [31], online surveys among participating GPs
and pharmacists revealed a discordance in opinions related
to support for the pharmacy initiative, with a 50/50 split
among GPs on whether pharmacy intervention increased or
decreased administrative burden. Moreover, 61% of GPs
voiced concern with respect to loss of patient data resulting
from incomplete reporting by pharmacists. Additionally,
GPs were concerned about the potential for reduced
quality of healthcare for their patients, safety issues and
personal ﬁnancial loss [31]. As such, there is need to ensure:
(i) adequate provision of additional pharmacist training; (ii)
the introduction of mechanisms for reimbursement; (iii) the
education of other healthcare professionals/the general
public in relation to the additional services offered by
community pharmacists; and (iv) that improvements are
made with respect to various aspects of administration,
including standardization of documentation and
health information technology integration across health
systems [14, 31].
Global feasibility. It is important to recognize that in some
low- and middle-income nations, adoption of an expanded
role of the community pharmacist may not be feasible due
to factors such as healthcare infrastructure, disparities in the
establishment, the availability and accessibility of
healthcare facilities, the shortage of qualiﬁed pharmacists
and associated training [74, 75], and, in many developing
countries, the perceived unimportance of a pharmacist's role
by the public/community and other healthcare providers
[76]. However, pharmacy practice is evolving in some
countries, such as China and India [76, 77]. For example, in
China, reform will enable community pharmacies to have
increased responsibility in primary healthcare over and
above the traditional role of dispensing and selling
medicines [77]. Although legislation/professional licensing
(i.e. regulations that limit the provision of services based on
speciﬁc government-established criteria) differs between
countries in terms of what a pharmacist can/cannot do [78],
international recognition of the value of an extended role
for pharmacists as healthcare providers is accumulating [74].
Conclusions
COPD represents a signiﬁcant personal and societal burden.
Lack of disease awareness, incorrect inhaler technique,
adherence and lifestyle practices may hamper any success
in the management of COPD, despite the availability of
effective and well-tolerated treatments and easy-to-use
inhalers. In this regard, pharmacists are well positioned to
play a vital role in all key stages of an integrated COPD
patient care pathway, from early detection/case ﬁnding
and support/monitoring of management plans to the provi-
sion of advice and counselling regarding medications,
inhaler technique and treatment adherence. Nevertheless,
current data are limited and this will necessitate further
exploration. In addition, more focused, global consider-
ations relating to improved pharmacist training in COPD,
reimbursement issues, increasing awareness of the pharma-
cist's role, and optimization of physician–pharmacist
collaboration are needed.
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